ArticleJournal of cellular and molecular medicine2016
P2Y12 antagonist attenuates eosinophilic inflammation and airway hyperresponsiveness in a mouse model of asthma.
Article in Journal of cellular and molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- The role of the P2X7 receptor in inactivated SARS-CoV-2-induced lung injury.Purinergic signalling · 2025Article
- Cysteinyl Leukotrienes in Allergic Inflammation.Annual review of pathology · 2025Review
- The Signaling Pathway of the ADP Receptor P2YInternational journal of molecular sciences · 2023Review
- Leukotrienes vs. Montelukast-Activity, Metabolism, and Toxicity Hints for Repurposing.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Emerging Roles of Platelets in Allergic Asthma.Frontiers in immunology · 2022Review
- Candida albicans elicits protective allergic responses via platelet mediated T helper 2 and T helper 17 cell polarization.Immunity · 2021Article
- Review
- The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma.Clinical and molecular allergy : CMA · 2021Article
- Administration of vitamin E attenuates airway inflammation through restoration of Nrf2 in a mouse model of asthma.Journal of cellular and molecular medicine · 2021Article
- Purinergic Receptors in the Airways: Potential Therapeutic Targets for Asthma?Frontiers in allergy · 2021Review
- LncRNA-AK149641 associated with airway inflammation in an OVA-induced asthma mouse model.Journal of bioenergetics and biomembranes · 2020Article
- P2YInternational journal of molecular sciences · 2020Review
- The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic.Frontiers in molecular biosciences · 2020Review
- P2YFrontiers in pharmacology · 2020Article
- ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12.Cell death & disease · 2019Article
- Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation.Purinergic signalling · 2019Article
- The synergistic effects of clopidogrel with montelukast may be beneficial for asthma treatment.Journal of cellular and molecular medicine · 2019Article
- Leukotriene receptors as potential therapeutic targets.The Journal of clinical investigation · 2018Review
- Platelet Munc13-4 regulates hemostasis, thrombosis and airway inflammation.Haematologica · 2018Article
- Targeting cell signaling in allergic asthma.Signal transduction and targeted therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukotriene E4 (LTE4) that plays a key role in airway inflammation is expressed on platelets and eosinophils. We investigated whether blocking of the P2Y12 receptor can suppress eosinophilic inflammation in a mouse model of asthma because platelets and eosinophils share this receptor to be activated. BALB/c mice were sensitized by intraperitoneal injection of ovalbumin (OVA), followed by OVA nebulization. On each challenge day, clopidogrel, a P2Y12 antagonist was administered 30 min. before each challenge. Forty-eight hours after the last OVA challenge, mice were assessed for airway hyperresponsiveness (AHR), cell composition and cytokine levels, including chemokine ligand 5 (CCL5), in bronchoalveolar lavage (BAL) fluid. EOL cells were treated with LTE4, with or without clopidogrel treatment, and intracellular and extracellular eosinophil cationic protein (ECP) expressions were measured to find the inhibiting function of P2Y12 antagonist on eosinophilic activation. The levels of P2Y12 expression were increased markedly in the lung homogenates of OVA-sensitized and -challenged mice after platelet depletion. Administration of clopidogrel decreased AHR and the number of airway inflammatory cells, including eosinophils, in BAL fluid following OVA challenge. These results were associated with decreased levels of Th2 cytokines and CCL5. Histological examination showed that inflammatory cells as well as mucus-containing goblet cells were reduced in clopidogrel-administered mice compared to vehicle-treated mice. Clopidogrel inhibited extracellular ECP secretion after LTE4 stimulation in EOL-1 cells. Clopidogrel could prevent development of AHR and airway inflammation in a mouse model of asthma. P2Y12 can be a novel therapeutic target to the suppression of eosinophils in asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.